Patients with poorly differentiated thyroid cancers (PDTC), anaplastic thyroid cancers (ATC),
and radioactive iodine-refractory (RAIR) differentiated thyroid cancers have a high mortality …

Background: Radioiodine (RAI) remains the mainstay of therapy for RAI-avid (RAIA) distant
metastatic thyroid carcinoma. We previously demonstrated that RAI-refractory distant …

Recurrent, metastatic disease represents the most frequent cause of death for patients with
thyroid cancer, and radioactive iodine (RAI) remains a mainstay of therapy for these patients …

Purpose: The extent to which routine genomic sequencing can identify relevant secondary
genomic alterations among BRAFV600E-mutant papillary thyroid carcinoma (PTC) is …

Context Little is known about the frequency of key mutations in thyroid cancer metastases
and its relationship with the primary tumor genotype. Objectives To evaluate the frequency of …

Purpose: The determinants of response or resistance to radioiodine (RAI) are unknown. We
aimed to identify genomic and transcriptomic factors associated with structural responses to …

The impact of BRAF mutations on the clinical outcomes of PTC remains debatable. In ATCs,
in turn, BRAF mutations identify patients eligible for targeted therapy, which is now …

Abstract Objective The BRAF V600E and TERT promoter mutations are well known to be
associated with poor clinical outcomes of papillary thyroid cancer (PTC). Radioactive iodide …

Summary Purpose BRAF V600E mutation represents the most common oncogenic event in
sporadic papillary thyroid cancer (PTC). There are, however, significant discrepancies …

Purpose: Papillary thyroid carcinoma (PTC), the most common thyroid malignancy, usually
possesses BRAF mutation or rearranged in translation (RET)/PTC rearrangements. PTC …